Published in Women's Health Weekly, July 15th, 2004
The study will enroll 48-60 patients and is designed to assess the safety and efficacy of A6 in asymptomatic women in clinical remission who have an elevated CA-125 tumor marker level following successful first line treatment.
Virgil Thompson, president and CEO of Angstrom said, "Our preclinical data show that A6 prevents metastases and inhibits tumor growth in animal models. We...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly